Pfizer views OTC business as very valuable asset

Pfizer views OTC business as very valuable asset

12 May 2016 - Deborah Wilkes

Download this NEWS EXTRA publication to read about recent developments at Pfizer Consumer Healthcare, including commitment to the business, switching, acquisitions and innovation.

Pfizer's chairman and chief executive officer Ian Read says Consumer Healthcare is currently a “very valuable asset” within Pfizer’s portfolio, but the US-based pharmaceutical company is “continually” reviewing all of its assets.

The Consumer Healthcare business reported strong growth in the first quarter of 2016, thanks largely to switching Nexium (esomeprazole) from prescription to OTC status. US sales rose by 16%, lifting worldwide sales by 10% on an operational basis.

This News Extra publication covers recent developments at Pfizer Consumer Healthcare, including switches, acquisitions, innovation collaborations and new products.

The publication is written by OTC industry expert Deborah Wilkes, who is the Editor & Publisher of OTCToolbox.

More than 3,000 words long, the publication is available to purchase and download immediately from the OTCToolbox website. You can make sure your team is well informed through a Multiple User Licence or a Global Licence.

The News Extra is available free to people with an Annual Subscription to the OTCToolbox website (click here to find out more).



RAPID INSIGHTS MADE EASY
AVAILABLE TO DOWNLOAD IMMEDIATELY AS A PDF
See Payment Options box at the top of this page

For alternative payment options and delivery methods, or other questions, please send an email to enquiries@otctoolbox.com.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to News Extras

Share this page: